SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Wu Alan)
 

Sökning: WFRF:(Wu Alan) > (2004) > Analytical and clin...

Analytical and clinical evaluation of the Bayer ADVIA Centaur automated B-type natriuretic peptide assay in patients with heart failure : a multisite study

Wu, Alan H B (författare)
Packer, Milton (författare)
Smith, Andrew (författare)
visa fler...
Bijou, Rachel (författare)
Fink, Daniel (författare)
Mair, Johannes (författare)
Wallentin, Lars (författare)
Uppsala universitet,Uppsala kliniska forskningscentrum (UCR)
Johnston, Nina (författare)
Uppsala universitet,Kardiologi
Feldcamp, Carolyn S (författare)
Haverstick, Doris M (författare)
Ahnadi, Charaf E (författare)
Grant, Andrew (författare)
Despres, Normand (författare)
Bluestein, Barry (författare)
Ghani, Farooq (författare)
visa färre...
 (creator_code:org_t)
2004-05-01
2004
Engelska.
Ingår i: Clinical Chemistry. - : Oxford University Press (OUP). - 0009-9147 .- 1530-8561. ; 50:5, s. 867-873
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • BACKGROUND:B-Type natriuretic peptide (BNP) is released from the left ventricle of the heart into the circulation in response to ventricular stretching and volume overload. Increased BNP concentrations are associated with heart failure (HF).METHODS:We evaluated the analytical and clinical performance of the Bayer ADVIA Centaur BNP assay. Studies included precision, analytical correlation (against the Shionogi ShionoRIA and Biosite Triage BNP assays), BNP results for blood collected in plastic tubes containing EDTA vs other collection tubes, high-dose hook effect, detection limits, and interferences. The clinical performance was tested on 2243 blood samples collected from 983 apparently healthy individuals, 538 patients with chronic disease but without HF (renal insufficiency, chronic obstructive pulmonary disease, diabetes, and hypertension), and 722 patients with HF (New York Heart Association classes I-IV).RESULTS:The ADVIA Centaur assay had total imprecision (CV) of 3.4%, 2.9%, and 2.4% at BNP concentrations of 48, 461, and 1768 ng/L, respectively. The Passing-Bablok correlations to the ShionoRIA and Triage were as follows: ADVIA Centaur = 1.11(ShionoRIA) - 1.19 ng/L (r = 0.98); ADVIA Centaur = 0.78(Triage) + 5.89 ng/L (r = 0.92), respectively. Of the different blood collection tubes, only EDTA plastic tubes (with and without the barrier gel) were acceptable. The lower detection limit was 0.5 ng/L, and there were no interferences from common analytes, other neuropeptides, or unusual antibodies. BNP exhibited different reference intervals according to age and gender. BNP concentrations increased progressively as the severity of HF increased.CONCLUSIONS:The ADVIA Centaur is the first commercially available BNP assay for use on an automated immunochemistry platform. This assay has good analytical and clinical performance characteristics for diagnosing HF.

Nyckelord

Adult
Aged
Aged; 80 and over
Autoanalysis
Female
Heart Failure; Congestive/*diagnosis
Humans
Male
Middle Aged
Natriuretic Peptide; Brain/*blood
ROC Curve
Reference Values
Sensitivity and Specificity

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy